Articles tagged with Ovarian Cancer
Researchers have identified eight protein biomarkers that enable accurate differentiation between endometrioid and high-grade serous ovarian carcinomas. This breakthrough could lead to more precise diagnosis and tailored treatment for patients, reducing the risk of undertreatment or overtreatment.
Researchers have successfully used circulating tumor DNA to monitor patient responses and find targeted treatments for ovarian cancer. The technique can detect genomic alterations in late-stage cancers, even when biopsies are difficult or impossible, and identify poor-responding patients after chemotherapy.
A recent clinical trial at the Stephenson Cancer Center found that patients with stage two, three, or four ovarian cancer can expect about 75 months of survival when their tumors are completely removed. The treatment regimen that caused fewer difficult side effects was just as effective as those with more severe side effects.
Researchers have identified 34 genes associated with an increased risk of developing the earliest stages of ovarian cancer. The study uses alternative splicing analysis to pinpoint these genes, which can help identify women at high risk and pave the way for new therapies.
Researchers at MIT have developed a novel fluorescence imaging system to improve surgery for ovarian cancer, enabling surgeons to detect and remove tumors as small as 0.3 millimeters. This technology has shown promising results in mice, with median survival rates 40% longer than those without image guidance.
A recent study found that fewer than a quarter of breast cancer patients and a third of ovarian cancer patients underwent genetic testing for cancer-associated mutations. The research, which analyzed data from over 83,000 women diagnosed with breast or ovarian cancer in California and Georgia between 2013 and 2014, revealed substantial...
Researchers at the University of Manchester have identified a new class of drugs that can stop ovarian cancer cells from growing. The PARG inhibitors target weaknesses in DNA replication, making them sensitive to these treatments.
A new diagnostic tool has been developed to detect ovarian cancer earlier, with high sensitivity and specificity rates. The test uses liquid biopsy proteomics to identify unique protein signatures in uterine fluid, promising improved detection rates for young women at high risk of developing the disease.
A new experimental drug, 673A, targets and annihilates stem-like ovarian cancer cells that cause recurrence. The treatment, combined with chemotherapy, resulted in significantly greater survival rates in a mouse model of ovarian cancer.
Scientists at FAU create porous scaffolds using electrospinning to support ovarian follicle growth, showing promising results. The goal is to develop an ideal artificial ovary that mimics the natural environment for follicle maturity, potentially increasing fertility in cancer patients.
Researchers at the University of Kansas have developed a 'lab-on-a-chip' that can detect cancer in a minuscule amount of plasma, leading to timelier interventions and better outcomes for patients. The device uses a 3D nanoengineering method to mix and sense biological elements more efficiently, enabling faster and cheaper detection.
Researchers from the University of Sheffield discovered a compound that kills cancer cells without triggering apoptosis, making it resistant to treatment. The new drug lead is highly active against treatment-resistant cancers and may be particularly effective against ovarian cancer.
Researchers developed AI software that predicts ovarian cancer prognosis and treatment effectiveness, outperforming existing methods by up to four times. The technology can stratify patients based on CT scan texture differences, enabling personalized medicine.
A two-year study found that out of 1919 women diagnosed with non-cancerous ovarian cysts, 20% had the cysts disappear on their own, and 80% either resolved or didn't require intervention. The risk of complications from surgical removal was lower than previously thought.
Losartan reduces extracellular matrix content and solid stress in ovarian tumors, increasing blood supply and drug delivery. The addition of losartan to chemotherapy agents could improve outcomes for patients with ovarian cancer.
A new study describes a novel approach to suppressing chemotherapy-induced tumor growth and recurrence in ovarian cancer. Researchers developed an anti-inflammatory drug called PTUPB that blocks the release of tumor-promoting chemicals by macrophages.
Researchers discovered that ovarian cancer cells colonize the omentum after being caught in DNA 'webs' extruded by immune cells. Inhibiting NET formation reduces metastasis in mice, suggesting a new approach to limit ovarian cancer spread. This study provides insights into improving ovarian cancer treatment.
A new blood test has been developed to detect early stage ovarian cancer using a bacterial toxin, with the test detecting significant levels of cancer glycan in over 90% of women with stage 1 ovarian cancer. The test also showed 100% accuracy for later stages of the disease and has potential for simple liquid biopsy monitoring.
A new photoacoustic imaging technique may help diagnose ovarian cancer at an early stage, improving survival rates. The technology uses transvaginal ultrasound and co-registered photoacoustic tomography to reveal information about tumor angiogenesis and blood oxygen saturation.
A new study of over 72,000 women found that simple ovarian cysts are normal and extremely common, with no association to a higher risk of ovarian cancer. Simple cysts should be considered normal findings in women of any age and can be safely ignored unless symptomatic.
Researchers at the University of Arizona are working on a disposable falloposcope to detect early-stage ovarian cancer. The device aims to reduce unnecessary procedures and improve patient outcomes by providing accurate screenings for high-risk women.
A University of Guelph study has found that opening up the blood vessels to an ovarian tumour can potentially improve the effectiveness of treatment. By creating a healthy blood supply, the tumour becomes more accessible to treatment, increasing success rates.
A phase 3 SOLO-1 trial found that olaparib maintenance therapy significantly improved progression-free survival (PFS) in newly diagnosed patients with advanced ovarian cancer and a BRCA1 or 2 mutation. The median PFS for those who received olaparib was approximately three years longer than the placebo group.
A study of 178 countries found a strong negative correlation between family size and cancer incidence, with larger families having a protective effect against various types of cancer. The protective effects are stronger for males than females, with non-reproduction-related cancers also being involved.
Researchers found that cancer cells from the fallopian tube affect ovary's chemical signaling, leading to increased norepinephrine levels, which drive cancer cell migration. This study highlights the importance of understanding chemistry in ovarian cancer development and treatment protocols.
Researchers discovered that mutations in the ARID1A gene lead to a molecular switch in the SWI/SNF protein complex, causing an increase in BCL2 expression and promoting tumor cell survival. Inhibiting BCL2 using a small molecule inhibitor kills ovarian cancer cells resistant to EZH2 inhibition.
A new study found that daily low-dose aspirin use reduces the risk of ovarian cancer by 23 percent. In contrast, heavy use of non-aspirin NSAIDs increases the risk. The research analyzed data from over 200,000 women and confirms earlier findings about aspirin's role in reducing certain types of cancers.
A recent study published in JAMA Oncology found that low-dose aspirin (100mg or less) reduces the risk of ovarian cancer by 23% compared to non-users. Long-term heavy use of non-aspirin NSAIDs may increase this risk.
A new cancer vaccine targeting HER2 has demonstrated clinical benefits in a phase I clinical trial, with six out of eleven evaluable patients experiencing improvements in their condition. The vaccine provided complete or partial responses and stable disease in some cases.
Researchers identified subtle epigenetic differences that explain why some ovarian cancer patients respond to PARPi drugs, while others do not. The study adds to a vital checklist for matching patients with the right therapy for their cancer.
A large study published by The BMJ found that newer combined oral contraceptives are associated with a reduced risk of ovarian cancer in young women. The positive effect strengthens with longer periods of use and persists for several years after stopping, providing reassurance for women.
Research teams identified CT45 as an independent prognostic factor for patients with high-grade serous ovarian cancer. High levels of CT45 were associated with extended disease-free survival, with patients living up to 7.5 years longer than those without sufficient CT45.
A new clinical trial suggests that combining CTLA4 targeted therapy with PD-1 targeted therapy may improve treatment outcomes for women with recurrent epithelial ovarian cancer. The trial found improved tumor response proportions and progression-free survival hazard rates in patients treated with the combination therapy.
Researchers have analyzed nearly 4,000 mutations in the BRCA1 gene, shedding light on its role in breast and ovarian cancer. The findings provide immediate benefits to patients with previously inconclusive genetic test results, enabling clinicians to better interpret variant of uncertain significance.
Researchers found that rapidly spreading ovarian cancer cells recruit CAFs to accelerate cancer proliferation and spread by enhancing energy sources. Blocking glycogen mobilization could be a therapeutic strategy for reducing tumor dissemination.
Researchers at UVA are developing a new antibody-based approach that combines targeting two receptors on ovarian cancer cells to increase its effectiveness. The approach has shown promising results in lab tests, with antibodies being more than 100 times more effective than existing therapies.
A study by University of Colorado Anschutz Medical Campus found that doctors with personal cancer experience are 17% more likely to recommend ovarian cancer screening to low-risk women, despite guidelines against it. This bias may be due to overestimating a patient's risk and prioritizing their experience over evidence-based guidelines.
A recent study found that only 8% of disabled or older women who qualified for Medicare received BRCA1 and BRCA2 testing between 2000 and 2014. Women with these mutations are at higher risk for developing second breast cancer and ovarian cancer, making timely testing crucial for informed decision-making.
Researchers found that normal fallopian tubes can contain pre-cancerous cells that escape and later progress to cancer in the pelvic or abdominal cavity. This 'precursor escape' concept may help explain why some women present with advanced ovarian cancer beyond the fallopian tubes.
Researchers at Johns Hopkins and Insilico Medicine discovered novel epigenetically silenced genes in ovarian cancer, including methylation of the GULP1 gene. GULP1 expression is associated with late-stage disease and poor overall survival, suggesting its potential as a biomarker.
Researchers have discovered that women with low-grade serous ovarian cancer and a BRAF gene mutation experience excellent responses to BRAF inhibitor treatments. This finding is encouraging for patients who may not respond to conventional chemotherapy.
Researchers at Rockefeller University have discovered the molecular means by which some cancers caused by BRCA1 mutations evade treatment by PARP inhibitors. The study challenges previous assumptions about the mechanics of these drugs and provides a foundation for advancements in PARP inhibitor therapy.
A large population study from Denmark found no causal association between assisted reproduction treatment and increased risk of ovarian cancer. Female infertility, rather than ovarian stimulation, was associated with an increased risk of ovarian cancer.
Researchers at Mayo Clinic have discovered how the DNA repair protein 53BP1 relocates to chromosomes to fix damage, using RNA molecules as an off/on switch. This finding could lead to new therapies for ovarian cancer by targeting a specific protein called TIRR.
A study of 99,654 individuals found that lifetime light alcohol drinkers had the lowest combined risk of mortality or developing cancer. The risk increased linearly with lifetime alcohol consumption, with heavy and very heavy drinkers facing significantly higher risks.
Researchers found a link between calcitriol and reduced ovarian cancer progression by blocking smad signaling in tumor cells and supportive fibroblasts. The study opens a new potential avenue for treating ovarian cancer, with calcitriol already FDA-approved for other uses.
The American Cancer Society report highlights a decline in ovarian cancer incidence and mortality rates in the US, with significant reductions seen among white populations. The strongest risk factor for ovarian cancer is a family history of breast or ovarian cancer, with BRCA1 and BRCA2 mutations accounting for nearly 40% of cases.
A population-based registry study confirms that secondary surgery can delay recurrence by two years and improve median overall survival by at least six years. The treatment model is centralized in Norway, which led to the favorable results, and may be adopted by other countries.
A cancer patient with advanced ovarian cancer responded well to treatment with hydroxychloroquine and quinacrine, initially prescribed for an autoimmune disease. The case report suggests that repurposing antimalarial drugs may improve cancer outcomes.
A phase II clinical trial suggests patients with aggressive pancreatic cancer who harbor BRCA mutations may benefit from rucaparib, a PARP inhibitor approved for ovarian cancer. The study found 32% of patients experienced a clinical benefit, including four patients with responses and two with stable disease.
Researchers have identified a key protein, MIP-1β, that enables ovarian cancer cells to spread through the peritoneal cavity by making mesothelial cells sticky. This discovery could lead to new therapies targeting this protein and its related adhesion protein P-selectin.
The study shows that ST1-ADC selectively inhibits tumor cell proliferation and induces tumor cell death in both in vitro and in vivo ovarian cancer models. The data provide promising results for the development of new therapeutic options to treat ovarian cancer.
PARP-1 levels are linked to targeted therapy resistance in ovarian cancer. Researchers have developed a method to image and measure PARP-1 using PET scans, which may predict efficacy and resistance to PARP inhibitors.
Researchers found that hemp extract slowed cell migration and reduced inflammation in ovarian cancer cells, suggesting a possible biological mechanism behind its anti-cancer effects. The study's results are comparable to or even better than current ovarian cancer drug Cisplatin, with potential for fewer side effects.
Researchers found tumors with PTEN loss are less likely to generate an immune response, suggesting PTEN levels can predict treatment outcome. The study's findings may improve personalized medicine for BRCA-deficient ovarian cancer patients.
A new personalized vaccine has shown promise in boosting immune responses and increasing survival rates in patients with advanced ovarian cancer. The vaccine combines different immunotherapies to better tackle the disease, which is often diagnosed at later stages and lacks curative treatment options.
The Rivkin Center awarded $1.185 million to ovarian cancer researchers worldwide, focusing on prevention and early detection, DNA repair, and novel therapies. This funding aims to improve early detection and discover new treatments for the deadly gynecological cancer.
Researchers developed a novel personalized vaccine made from tumor tissue and immune cells, inducing potent immune responses in patients with recurrent ovarian cancer. The vaccine showed promise in extending overall survival and improving progression-free survival.
Ludwig scientists present new data on cancers including colorectal, brain, breast, and ovarian cancer, as well as innovative clinical trials and novel approaches to cancer immunotherapy. The research focuses on mobilizing immunity against ovarian cancer and personalizing cancer treatment strategies.
The Translational Genomics Research Institute (TGen) will receive $450,000 to fund a clinical trial for a newly developed ovarian cancer drug treatment, thanks to Colleen's Dream Foundation. The foundation has funded TGen in the past and has awarded over $1.2 million in grants to 27 institutions.